



HAL
open science

Nonoptimal Vaginal Microbiota after Azithromycin Treatment for Chlamydia trachomatis Infection

Jeanne Tamarelle, Bing Ma, Pawel Gajer, Michael S. Humphrys, Mishka Terplan, Katrina S. Mark, Anne C.M. Thiébaud, Larry J. Forney, Rebecca M. Brotman, Elisabeth Delarocque-Astagneau, et al.

► **To cite this version:**

Jeanne Tamarelle, Bing Ma, Pawel Gajer, Michael S. Humphrys, Mishka Terplan, et al.. Nonoptimal Vaginal Microbiota after Azithromycin Treatment for Chlamydia trachomatis Infection. *Journal of Infectious Diseases*, 2020, 221 (4), pp.627-635. 10.1093/infdis/jiz499 . hal-03228157

HAL Id: hal-03228157

<https://hal.science/hal-03228157>

Submitted on 10 Jun 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Nonoptimal Vaginal Microbiota After Azithromycin Treatment for *Chlamydia trachomatis* Infection

Jeanne Tamarelle,¹ Bing Ma,^{2,3} Pawel Gajer,^{2,3} Mike S. Humphrys,² Mishka Terplan,^{4,a} Katrina S. Mark,⁴ Anne C. M. Thiébaud,¹ Larry J. Forney,⁵ Rebecca M. Brotman,^{2,6} Elisabeth Delarocque-Astagneau,¹ Patrik M. Bavoil,⁷ and Jacques Ravel^{2,3,6}

¹Unité Mixte de Recherche 1181, Université Versailles-Saint-Quentin-en-Yvelines, Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Paris, France, ²Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA, ³Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA, ⁴Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore, Maryland, USA, ⁵Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore, Maryland, USA, ⁶Department of Biological Sciences, University of Idaho, Moscow, Idaho, USA, ⁷Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA, and ⁷Department of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, Maryland, USA

We characterized the composition and structure of the vaginal microbiota in a cohort of 149 women with genital *Chlamydia trachomatis* infection at baseline who were followed quarterly for 9 months after antibiotic treatment. At time of diagnosis, the vaginal microbiota was dominated by *Lactobacillus iners* or a diverse array of bacterial vaginosis-associated bacteria including *Gardnerella vaginalis*. Interestingly, *L. iners*-dominated communities were most common after azithromycin treatment (1 g monodose), consistent with the observed relative resistance of *L. iners* to azithromycin. *Lactobacillus iners*-dominated communities have been associated with increased risk of *C. trachomatis* infection, suggesting that the impact of antibiotic treatment on the vaginal microbiota could favor reinfections. These results provide support for the dual need to account for the potential perturbing effect(s) of antibiotic treatment on the vaginal microbiota, and to develop strategies to protect and restore optimal vaginal microbiota.

Keywords. vaginal microbiome; sexually transmitted infection; *Chlamydia trachomatis*; antibiotics; 16S rRNA gene sequencing; longitudinal.

In the United States, >1.7 million *Chlamydia trachomatis* (CT) genital infections were reported in 2017 (528.8 cases per 100 000), representing a 6.9% increase since 2016 [1]. However, this rate is considered an underestimate, as most CT-positive cases are asymptomatic [2]. CT infection is particularly prevalent in females between the ages of 15 and 24 years, with a reported infection rate 4 times higher than the general population [3]. Without appropriate treatment, approximately 10%–20% of infected women develop pelvic inflammatory disease [4, 5], which is associated with tubal infertility and ectopic pregnancy [6].

The vaginal microbiota provides the first line of defense against sexually transmitted infections (STIs). *Lactobacillus*

spp produce lactic acid and other antimicrobial compounds that maintain a protective environment [7]. The absence of *Lactobacillus* spp, as in the clinical diagnosis of bacterial vaginosis (BV), is associated with increased risk of STIs [8–12]. CT transmission rates after exposure to an infected partner are estimated at between 25% and 40% [13–15], indicating that not all exposures result in successful infection and that other factors, such as the vaginal microbiota, could be important cofactors in susceptibility to infection. Recent large-scale molecular surveys of the vaginal microbiota have revealed 5 broad vaginal bacterial community-state types (CSTs) [16, 17]. Four CSTs are dominated by *Lactobacillus* spp, while a fifth is deficient in *Lactobacillus* but comprised of a diverse set of strict and facultative anaerobes as often seen in BV. It has been hypothesized that different CSTs respond differently to disturbance events such as menstruation and medication [16–20] and display different resilience, that is, the ability to respond to, withstand, and recover from disturbance [21]. We sought to evaluate if the vaginal microbiota returns to a more optimal state following antibiotic treatment for genital CT infection. If the vaginal microbiota is not fully restored in the months and years following CT treatment, it may help to explain observed high rates of CT reinfection [22, 23]. We aimed to characterize the vaginal microbiota composition and structure of a cohort of 149 women with genital CT infection who were followed quarterly for 9 months after azithromycin treatment.

Received 2 July 2019; editorial decision 21 September 2019; accepted 27 September 2019; published online October 1, 2019.

Presented in part: Keystone Symposium, “Role of the Genital Tract Microbiome in Sexual and Reproductive Health (S6),” Cape Town, South Africa, 11–16 December 2018.

^aPresent affiliation: Virginia Commonwealth University, Department of Obstetrics and Gynecology, Richmond, Virginia.

Correspondence: Jacques Ravel, PhD, Institute for Genome Sciences, University of Maryland School of Medicine, 670 W Baltimore St, Baltimore, MD 21201 (jravel@som.umaryland.edu).

The Journal of Infectious Diseases® 2020;221:627–35

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/infdis/jiz499

METHODS

Study Design

Adolescents and young adults with positive tests for CT infection were screened at clinic point-of-care centers and community-based outreach sites by clinical staff at the University of Maryland School of Medicine's Adolescent and Young Adult Center. Participants in the Chlamydia Adolescent/Adult Reproductive Management (CHARM) research study were invited upon notice of positive CT infection. The study was approved by the institutional review board of the University of Maryland, Baltimore (protocol number HP-00042350). Included in this report are eligible females who were 12–40 years old and self reported a history of sexual activity. The CHARM cohort is described in detail elsewhere [24]. In addition, 99 CT-negative African American women, 19–44 years old, enrolled in the Vaginal Microbiota 400 Women Study (VM400) [17], a cross-sectional study at the University of Maryland School of Medicine, served as controls.

Study Procedure

At each CHARM enrollment visit (enrollment, 3 months, 6 months, and 9 months), an audio computer-assisted self-interview was administered. Clinicians conducted a physical examination and specimen collection, and provided treatment for CT using azithromycin 1 g orally in a single dose. When women were CT positive at visit 2, 3, or 4, azithromycin treatment was prescribed as needed and women remained in the study. Vaginal specimens for microbiota analysis (ESwabs, Copan) were collected from the mid-vaginal wall prior to antibiotic treatment, stored in 1 mL liquid Amies, and archived at -80°C . CT was determined by BD ProbeTec on urine specimens.

Sample Processing, 16S Ribosomal RNA Gene Amplification, and Sequencing

Whole genomic DNA was extracted from 300- μL aliquots of Amies solution as previously reported [17]. High-throughput amplification and sequencing of the V3–V4 hypervariable regions of the 16S ribosomal RNA gene were performed using a validated and improved dual-indexing approach [25]. Further bioinformatic processing followed the DADA2 Workflow for Big Data and *dada2* (version 1.5.2) (<https://benjjneb.github.io/dada2/bigdata.html> [26]) as previously reported [27]. Taxonomy was assigned to each amplicon sequence variant generated by *dada2* using SpeciateIt (version 1.0, <http://ravel-lab.org/SpeciateIt>). Read counts for amplicon sequence variants assigned to the same taxonomy were summed for each sample. Data analyses include hierarchical clustering of each community profiles using Euclidian distance and assignment to one of the CSTs described previously [16, 17], and community diversity estimation using the Shannon diversity index [28].

Statistical Analyses

Analyses were carried out on samples with a total read count of at least 1000, and on phylotypes present in at least 2 samples.

Baseline characteristics between CHARM participants who were lost to follow-up after the first visit and those who did not were compared using Fisher tests. To compare vaginal microbiota composition and structure among different groups, we conducted analyses at the CST and at the phylotype levels. At the phylotype level, we fitted negative binomial regression models for each phylotype present in at least 20% of all samples, using the DESeq2 package in R [29]. At the CST level, we fitted logistic regression models to compare vaginal microbiota of CHARM visit 1 (CT positive) or CHARM visit 2 to those of the VM400 controls. We applied a mixed-effect logistic regression model to compare CHARM visit 1 and visit 2 taking into account intrawoman correlation between samples, using the lme4 package in R. To describe vaginal microbiota at all visits and in the VM400 cohort controls, we used the Shannon diversity index, which accounts for both the number of different taxa and their evenness. Values of the Shannon diversity index were compared across CHARM visits and with the VM400 controls using the Wilcoxon matched-pairs signed-rank test and the Wilcoxon–Mann–Whitney rank-sum test, respectively. For all these analyses, CT-positive samples at visits 2, 3, and 4 were excluded because of the difficulty to distinguish between reinfections and treatment failures (see Results).

RESULTS

We enrolled 149 women with confirmed CT infection, mostly African American (86%) and 13–33 years old who provided 141 baseline samples (visit 1), prior to treatment with 1 g single-dose azithromycin. Additional samples were collected at each subsequent visit and tested for CT (92, 85, and 77 samples, respectively; [Supplementary Figure 1](#)). CT positivity was 18% ($n = 17$), 14% ($n = 12$), and 18% ($n = 14$), respectively.

Participants' demographic, behavioral, and medical history is summarized in [Supplementary Table 1](#). Women lost to follow-up after visit 1 ($n = 49$) were less likely to have pelvic inflammatory disease at baseline (data not shown); no other baseline characteristics were significantly associated with cohort retention ($n = 100$), including age, race, marital status, education, sexual orientation, number of partners (lifetime and in the last 3 months), smoking status, Nugent score, hormonal contraception, or CST.

For the CHARM cohort, we obtained 7 396 180 high-quality sequences with an average of 18 725 (standard deviation [SD], 18 325) sequences per sample. For the VM400 controls, we generated 3 349 907 sequences with an average of 33 837 (SD, 17 024) sequences per sample. A total of 319 phylotypes was identified in the combined CHARM and VM400 datasets. The relative abundance of each phylotype is illustrated in [Figure 1](#) (data available at https://github.com/ravel-lab/charm_longitudinal).

Vaginal Microbiota Composition Association With Prevalent CT Infection

To lower the dimensionality of the dataset, samples were assigned to CSTs. CST I and III are often dominated by *Lactobacillus*

crispatus and *Lactobacillus iners*, respectively, whereas CST IV lacks *Lactobacillus* spp and includes a diverse array of facultative and strict anaerobes. Further refinement revealed subtypes CST III-A/B and IV-A/B (Figure 1). Broadly, in CST III-A, *L. iners* is dominating the vaginal community at a relative abundance higher than approximately 80%, whereas in CST III-B, *L. iners* remains the dominant species but at lower abundance while anaerobes are also present. Within CST IV, CST IV-B is represented by a higher abundance of *Gardnerella vaginalis*.

Using a logistic regression model, we found that the frequencies of each CST in CHARM visit 1 and VM400 cohort control samples were significantly different (Supplementary Table 2). We observed that CST III-A, CST III-B, CST IV-A, and CST IV-B were significantly overrepresented in CHARM samples compared to controls (odds ratios [ORs], 4.51 [95% confidence interval {CI}, 1.41–16.42], 5.20 [95% CI, 1.66–18.72], 8.98 [95% CI, 3.38–28.59], and 26.52 [95% CI, 8.84–94.91], respectively;

P values .015, .007, < .001, and < .001, respectively) (Figure 2). The majority of CST IV samples (91%) were confirmed to have Nugent scores >7, which is indicative of BV [31].

We fitted a negative binomial regression model to evaluate specific phylotypes associated with CT infection (visit 1) compared to the control group. We compared the relative abundance of 40 phylotypes present in at least 20% of controls and CHARM visit 1 samples (240 observations). Phylotypes significantly associated with either CHARM visit 1 or VM400 cohort controls are listed in Supplementary Table 3. Overall, 25 phylotypes had relative abundance that significantly differed between the 2 groups (Supplementary Figure 2), among which 11 phylotypes were overrepresented in CT-positive vaginal microbiota, including *G. vaginalis*, *Atopobium vaginae*, bacterial vaginosis-associated bacterium (BVAB) 2, and *Mobiluncus curtisii*, whereas *Lactobacillus* spp were overrepresented in VM400 CT-negative samples.




Figure 1. Heatmap representing the relative abundance of the 20 most abundant phylotypes found in the vaginal microbiota of 395 samples collected every 3 months for 9 months after azithromycin treatment for *Chlamydia trachomatis* by 149 young females in the Chlamydia Adolescent/Adult Reproductive Management prospective cohort, Baltimore, Maryland, and 99 samples from 99 women enrolled in the VM400 cross-sectional control study, Baltimore, Maryland [30]. Ward linkage clustering was used to cluster samples based on their Euclidian distance calculated in the “vegan” package in R. The 4 bars on top indicate community state types, according to the previous naming convention [30], Nugent Score, vaginal pH, and visit number. Abbreviations: BVAB, bacterial vaginosis-associated bacteria; CHARM, Chlamydia Adolescent/Adult Reproductive Management; CST, community state types.




Figure 2. Proportions of community state types (CSTs) in Chlamydia Adolescent/Adult Reproductive Management (CHARM) samples from visit 1 (*Chlamydia trachomatis* [CT] positive) and visit 2 (CT negative, 3 months posttreatment) and in VM400 controls.

CT Infection and Antibiotic Treatment Footprint on the Vaginal Microbiota

All women from the CHARM study were treated with azithromycin after a CT-positive diagnosis at baseline. Interestingly, 18% ($n = 17$) of women were CT positive at visit 2 (either because of treatment failure, reinfection with the same untreated partner, or reinfection with another partner). The frequency of each CST at visit 2 in CT-negative women ($n = 74$) were compared to that of the VM400 cohort (cleared infection vs noninfected). We observed that CST III-A, CST III-B, CST IV-A, and CST IV-B were again overrepresented in CHARM CT-negative samples (ORs, 5.89 [95% CI, 1.91–21.01], 3.81 [95% CI, 1.16–14.13], 3.47 [95% CI, 1.23–11.47], and 9.88 [95% CI, 3.09–36.88]), respectively; P values .003, .033, .027, and < .001, respectively) (Supplementary Table 4 and Figure 2). At the phylotype level, among 49 phylotypes present in at least 20% of CHARM visit 2 CT-negative and VM400 control samples (173 observations), 24 were statistically significant with 6 overrepresented in CHARM CT-negative samples compared to controls, including *A. vaginae*, *Gemella haemolysans*, or *Peptoniphilus gorbachii*. However, *G. vaginalis*, BVAB1, BVAB2, and, interestingly, *L. iners*, were not statistically significant but trended toward overrepresentation in CHARM CT-negative samples (Supplementary Table 5 and Supplementary Figure 3).

Additionally, the frequency of CSTs in CHARM visit 2 CT-negative samples was compared to that of CHARM visit 1

(CT-positive). CST III-A was overrepresented in CT-negative samples compared to CT-positive samples (Supplementary Table 6 and Figure 2) (OR, 3.51 [95% CI, 1.45–8.75], using CST IV-B as reference). In addition, among 33 phylotypes present in at least 20% of CHARM visit 1 and visit 2 CT-negative samples (215 observations), only *L. iners* appeared to be significantly overrepresented in CT-negative samples at visit 2 compared to visit 1 samples (negative \log_2 fold change), this after correcting for multiple testing (Supplementary Table 7 and Supplementary Figure 4).

Long-Lasting Effect of CT Infection and Azithromycin Treatment on the Vaginal Microbiota

The composition and structure of the vaginal microbiota in CT-negative samples at visit 3 and visit 4 (6 months and 9 months after azithromycin treatment: $n = 73$ and $n = 63$, respectively) were analyzed to evaluate whether CT infection and azithromycin treatment had a long-term effect on the vaginal microbiota. While a major shift in CST was observed between visit 1 and visit 2 (probably due to CT infection and azithromycin treatment as suggested above), the proportions of CST III and CST IV remained stable from visit 2 to visit 4 while women remained CT negative (Figure 3). Interestingly, *L. iners* relative abundance increased greatly after azithromycin treatment (visit 1 to visit 2; Figure 4A) whereas *Sneathia sanguinegens* decreased, but the relative abundance of no phylotype was statistically significantly different between visit 2 and visit 4 (Figure 4B and 4C). Shannon diversity was significantly higher in CHARM visit 1 samples compared to other CHARM samples and VM400 samples, and no difference was found between visits 2, 3, and 4 (Supplementary Table 8 and Supplementary Figure 5).

L. iners and *G. vaginalis* Strain Resistance to Azithromycin

To evaluate whether the patterns we observed were associated with antibiotic resistance of phylotypes associated with CST IV (*G. vaginalis*) and CST III (*L. iners*), we performed antimicrobial susceptibility tests of 2 front-line antibiotic treatments for CT genital infection, azithromycin and doxycycline, on several strains of these 2 species (Figure 5 and Supplementary Table 9). We observed low resistance to azithromycin (0.094–1.5 $\mu\text{g}/\text{mL}$) for *L. crispatus*, *Lactobacillus jensenii*, and *Lactobacillus gasseri*; however, some *L. iners* (5/10) and *G. vaginalis* (1/8) strains were resistant to the highest concentration of azithromycin tested (256 $\mu\text{g}/\text{mL}$). In contrast, doxycycline sensitivity was similar for all inspected vaginal species (0.016–12 $\mu\text{g}/\text{mL}$), and no doxycycline resistance was observed.

Community-State Types Transition Patterns From One Visit to Another According to CT Infection Status

For each CHARM participant with follow-up samples ($n = 100$), we generated CST transition patterns over the course of the




Figure 3. Community state type (CST) proportions in Chlamydia Adolescent/Adult Reproductive Management (CHARM) samples from visit 1 (*Chlamydia trachomatis* [CT] positive, pretreatment), visit 2 (CT negative only, 3 months posttreatment), visit 3 (CT negative only, 6 months posttreatment), and visit 4 (CT negative only, 9 months posttreatment) and in VM400 controls.

study (Figure 6A). Analysis of individual trajectories confirmed our findings that women commonly transitioned to *L. iners*-dominated CST III-A after azithromycin treatment. However, over time, women who were CST IV-A and CST IV-B before treatment and transitioned to CST III at visit 2 then transitioned back to CST IV or CST III-B, which both contain significant levels of strict and facultative anaerobes. We further stratified these CST transition patterns by restricting the analysis to (1) participants who shifted from CT positive at visit 1, 2, or 3 to CT negative at the following visit (Figure 6B); (2) participants

who remained CT negative for 2 consecutive visits (Figure 6C); and (3) participants who tested CT negative at visit 2 or 3 but CT positive at the following visit (Figure 6D).

Transitions from CT positive to CT negative (Figure 6B) at any time during the study period (after azithromycin treatment) were mostly associated with a transition to CST III-A (+75%), supporting the findings obtained when comparing CHARM visit 1 (CT positive) to CHARM visit 2 (CT negative). These transitions were observed in women who were either CST III-B or CST IV-A/B when CT positive. Surprisingly, CST I was observed after




Figure 4. Volcano plots displaying results of negative binomial regression model using the DESeq2 package on R [29], comparing phylotypes differentially expressed between Chlamydia Adolescent/Adult Reproductive Management (CHARM) samples: visit 1 (*Chlamydia trachomatis* [CT] positive) to visit 2 (CT negative) (A), visit 2 (CT negative) to visit 3 (CT negative) (B), visit 3 (CT negative) to visit 4 (CT negative) (C), for phylotypes present in at least 20% of samples for each analysis (33, 32, and 34 phylotypes, respectively). The \log_2 fold change is plotted against the $-\log_{10}$ of the Q value, which is the P value corrected for multiple testing using Benjamini–Hochberg correction (BH). Positive values of the \log_2 fold change indicate phylotypes overrepresented in the first visit of the 2 visits considered, whereas negative values indicate phylotypes overrepresented in the second visit.




Figure 5. Antimicrobial susceptibility test of 5 major vaginal bacterial species for azithromycin and doxycycline. Minimum inhibitory concentration (MIC) was determined by broth microdilution protocol [32] with concentrations ranging from 0.016 µg/mL to 256 µg/mL. Number of strains tested: *Gardnerella vaginalis*: 8; *Lactobacillus crispatus*: 6; *Lactobacillus gasseri*: 5; *Lactobacillus iners*: 10; *Lactobacillus jensenii*: 3.

azithromycin treatment, despite the fact that in vitro *L. crispatus* was shown to be sensitive to azithromycin. As expected, in the absence of azithromycin treatment (CT negative at 2 consecutive

visits; Figure 6C), we observed limited CST transitions that did not affect the overall CST proportions (Figure 3). Transitions between CST III-B and CST IV-A were rare, whereas subgroup transitions within CST IV and within CST III were more frequent. We also observed very few transitions between CST I and CST IV-B (n = 1 of 61 transitions overall) or CST IV-A (n = 1 of 61) (Supplementary Figure 6 and Supplementary Table 10). In cases of transitions from CT negative to CT positive, there was an increase of CST III-B (+150%) and CST IV-B (+33%), though numbers were too small to draw any conclusions. As expected, no transition to CST I was observed (Figure 6D).

DISCUSSION

By evaluating the vaginal microbiota composition and structure at time of CT infection and every 3 months for 9 months after azithromycin treatment, our study identified specific characteristics of the vaginal microbiota associated with CT infection and resolution. Unsurprisingly, the vaginal microbiota of women infected with CT in CHARM encompassed bacterial taxa commonly associated with BV or CST IV, including *G. vaginalis*, *A. vaginae*, or *M. curtisii* [33–37]. It is important to note that studies of the vaginal microbiota during prevalent CT infection do not resolve whether the observed microbiota is causal to the increased risk of CT infection, or if it is a consequence of CT infection. To potentially establish causality, prospective longitudinal studies must be performed and focused on incident cases of infection. Such a study undertaken in the Netherlands has indicated that women presenting an *L. iners*-dominated CST




Figure 6. Transitions between community state types (CSTs) from one visit to another in Chlamydia Adolescent/Adult Reproductive Management (CHARM) samples. A, Individual trajectories of women included in the study. B, CST transitions from *Chlamydia trachomatis* (CT)-positive samples pretreatment to CT-negative samples posttreatment at 2 consecutive visits. C, CST transitions among CT-negative samples at 2 consecutive visits. D, CST transitions from CT-negative samples to CT-positive samples at 2 consecutive visits. The number next to a line represents the number of women transitioning from one CST to another. Looped arrows represent the number of women staying in the same CST between 2 visits and are colored green. In B, C, and D, circle size is proportional to total frequency of CSTs.

III were at increased risk of CT infection compared to women with *L. crispatus*-dominated CST I [38]. While *L. iners* often dominates CST III, it can share the ecological niche with other bacterial taxa, such as *G. vaginalis*, *A. vaginae*, and other strict and facultative anaerobes, whose presence could limit the potential benefit of having a *Lactobacillus* spp–dominated vaginal microbiota. When that is the case, CST III is thought to transition more frequently to CST IV, as previously observed in longitudinal studies of the vaginal microbiota [16, 18], particularly following antibiotic treatment for BV [20]. Importantly, it is well established that CST IV is associated with an increased risk for CT infection [12, 39].

The longitudinal study design of CHARM gave us the unique opportunity to observationally study the vaginal microbiota following azithromycin treatment. Interestingly, we found that 3 months after azithromycin treatment for CT infection, most women had vaginal microbiota that were either CST IV or CST III-A. The relative frequency of each CST in CT-negative women at visit 2 was significantly different from that observed in our control CT-negative cohort drawn from the same clinic. Modeling the transitions from visit 1 to visit 2 demonstrated that after azithromycin treatment, *L. iners* relative abundance (and CST III) increases substantially. Because of the observational and interval censored study design, we cannot differentiate azithromycin's direct effects (observed 3 months later) vs the community changes resulting from CT clearance. However, we hypothesize that the observed microbiota could be explained by either the effect of antibiotic exposure or by a return to a preinfection vaginal microbiota or a combination of both. We observed that strains of *L. iners* and *G. vaginalis* displayed a higher level of resistance to azithromycin, and thus could be selected posttreatment, whereas sensitive *Lactobacillus* spp were diminished. Nonetheless, because *L. iners* is a potential risk factor for CT infection [40], this finding is important as it suggests that after antibiotic treatment, a woman's risk of STI is not reduced. This result could contribute significantly to the high rate of reinfections observed in CHARM and in other studies (20–30 cases per 100 person-years [22, 23]). In our cohort, 74.2% of women reported at baseline having been CT positive in the last 3 months. Though this could be due to (re-)exposure to infected partners, it is likely that they received antibiotic treatment, thus maintaining their susceptibility to reinfection. Another study evaluating the effect of metronidazole treatment for BV showed that *L. iners* was often increased after antibiotic treatment, sometimes replacing *G. vaginalis* [20]. Thus metronidazole treatment can also result in nonoptimal vaginal microbiota. More importantly, we provide evidence that a posttreatment vaginal microbiota remains stable for up to 9 months with high relative abundances of *L. iners* and *G. vaginalis*, resulting in persistently increased CT infection risk.

Interestingly, doxycycline, another recommended antibiotic for CT infection, efficiently killed all strains tested in

our minimum inhibitory concentration studies. Though both antibiotics are reported to be 95% effective to treat CT infection, a meta-analysis reported doxycycline as more effective than azithromycin [41]. If, in vivo, azithromycin eliminates *L. crispatus*, *L. jensenii*, and *L. gasseri*, which are considered beneficial [42–47], the treatment would favor the proliferation of *L. iners* or *G. vaginalis*, thus increasing the risk of CT infection. This result is novel since only one previous study reported no effect of azithromycin on 4 strains of *G. vaginalis* and 2 of *L. iners* [48]. This finding supports the use of live biotherapeutic products to restore a protective vaginal microbiota after antibiotic treatment for CT and potentially for other health conditions treated by antibiotics. Unfortunately, very little is known about the effect of frequently used antibiotics on the vaginal microbiota.

Our study presents some limitations. Owing to our inclusion criteria focusing on CT-positive women at baseline, we are unable to determine whether bacterial phylotypes and CSTs overrepresented in CHARM visit 1 CT-positive samples were present before infection. Similarly, we are unable to distinguish between CT clearance or antibiotic treatment as the causal determinant in microbiota composition. However, we found that some strains of *L. iners* and *G. vaginalis* are resistant to azithromycin, which could explain the observed patterns. Unfortunately, the study was not sufficiently powered to detect a statistically significant impact of reinfection at visits 3 or 4. Finally, we used a cohort of 99 healthy African American women from the same geographical area and clinic for recruitment as a control population in our analyses. However, the CHARM cohort is not entirely African American (87.4%), and we cannot exclude that they differ for other characteristics.

This study has potentially important consequences for the management and control of CT infections. It confirms the association between CT infection and not only non-*Lactobacillus* spp microbiota, but also microbiota dominated by *L. iners*. Furthermore, the study shows that high risk for infection may be maintained in part by antibiotic treatment. Our results stress the importance of taking into account the potential perturbing effects of antibiotic treatment on the vaginal microbiota, whether it is for the treatment of CT infections or other indications. Studies of the effect of antibiotic therapy on the composition of the vaginal microbiota are urgently needed. Such studies will provide the necessary guidance in the development of strategies to protect and restore optimal vaginal microbiota composition prior to and after antibiotic treatment.

Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. The authors thank the participants of the CHARM and VM400 studies and the clinical team for their assistance in recruiting participants. The authors also thank Elias McComb for technical help with the antibiograms assays.

Disclaimer. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health (NIH), the Institut Pasteur, or the University of Maryland School of Medicine.

Financial support. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the NIH (award numbers U19AI084044, UH2AI083264, and R21AI130627). J. T. was supported by a fellowship from the Région Ile-de-France.

Potential conflicts of interest. J. R. is co-founder of LUCA Biologics, a biotechnology company focusing on translating microbiome research into live biotherapeutics drugs for women's health. All other authors report no potential conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

- Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2017. Atlanta, GA: CDC, 2018.
- Zimmerman HL, Potterat JJ, Duker RL, et al. Epidemiologic differences between chlamydia and gonorrhea. *Am J Public Health* 1990; 80:1338–42.
- Centers for Disease Control and Prevention. STD rates by age. <https://www.cdc.gov/std/stats18/adolescents.htm>. Accessed 3 July 2019.
- Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for *Chlamydia trachomatis* to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. *BMJ* 2010; 340:c1642.
- Price MJ, Ades AE, Welton NJ, Simms I, Macleod J, Horner PJ. Proportion of pelvic inflammatory disease cases caused by *Chlamydia trachomatis*: consistent picture from different methods. *J Infect Dis* 2016; 214:617–24.
- Carey AJ, Beagley KW. *Chlamydia trachomatis*, a hidden epidemic: effects on female reproduction and options for treatment. *Am J Reprod Immunol* 2010; 63:576–86.
- Ma B, Forney LJ, Ravel J. Vaginal microbiome: rethinking health and disease. *Annu Rev Microbiol* 2012; 66:371–89.
- Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis is a strong predictor of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* infection. *Clin Infect Dis* 2003; 36:663–8.
- Peters SE, Beck-Sagué CM, Farshy CE, et al. Behaviors associated with *Neisseria gonorrhoeae* and *Chlamydia trachomatis*: cervical infection among young women attending adolescent clinics. *Clin Pediatr (Phila)* 2000; 39:173–7.
- Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. *J Infect Dis* 1999; 180:1863–8.
- Cherpes TL, Meyn LA, Krohn MA, Lurie JG, Hillier SL. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. *Clin Infect Dis* 2003; 37:319–25.
- Brotman RM, Klebanoff MA, Nansel TR, et al. Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. *J Infect Dis* 2010; 202:1907–15.
- Quinn TC, Gaydos C, Shepherd M, et al. Epidemiologic and microbiologic correlates of *Chlamydia trachomatis* infection in sexual partnerships. *JAMA* 1996; 276:1737–42.
- Lycke E, Löwhagen GB, Hallhagen G, Johansson G, Ramstedt K. The risk of transmission of genital *Chlamydia trachomatis* infection is less than that of genital *Neisseria gonorrhoeae* infection. *Sex Transm Dis* 1980; 7:6–10.
- Katz BP. Estimating transmission probabilities for chlamydial infection. *Stat Med* 1992; 11:565–77.
- Gajer P, Brotman RM, Bai G, et al. Temporal dynamics of the human vaginal microbiota. *Sci Transl Med* 2012; 4:132ra52.
- Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A* 2011; 108(Suppl 1):4680–7.
- Ravel J, Brotman RM, Gajer P, et al. Daily temporal dynamics of vaginal microbiota before, during and after episodes of bacterial vaginosis. *Microbiome* 2013; 1:29.
- Macklaim JM, Fernandes AD, Di Bella JM, Hammond JA, Reid G, Gloor GB. Comparative meta-RNA-seq of the vaginal microbiota and differential expression by *Lactobacillus iners* in health and dysbiosis. *Microbiome* 2013; 1:12.
- Srinivasan S, Liu C, Mitchell CM, et al. Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. *PLoS One* 2010; 5:e10197.
- Relman DA. The human microbiome: ecosystem resilience and health. *Nutr Rev* 2012; 70(Suppl 1):S2–9.
- Walker J, Tabrizi SN, Fairley CK, et al. *Chlamydia trachomatis* incidence and re-infection among young women—behavioural and microbiological characteristics. *PLoS One* 2012; 7:e37778.
- Scott Lamontagne D, Baster K, Emmett L, et al; Chlamydia Recall Study Advisory Group. Incidence and reinfection rates of genital chlamydial infection among women aged 16–24 years attending general practice, family planning

- and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia Recall Study Advisory Group. *Sex Transm Infect* **2007**; 83:292–303.
24. Mark K, Martinez-Greife S, Bavoi P, Brotman R, Terplan M, Ravel J. Chlamydia in adolescent/adult reproductive management trial study (CHARM): clinical core protocol. *Contemp Clin Trials* **2019**. Available at: <https://www.sciencedirect.com/science/article/pii/S2451865419300936>.
 25. Fadrosch DW, Ma B, Gajer P, et al. An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform. *Microbiome* **2014**; 2:6.
 26. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. *Nat Methods* **2016**; 13:581–3.
 27. Holm JB, Humphrys MS, Robinson CK, et al. Ultrahigh-throughput multiplexing and sequencing of >500-base-pair amplicon regions on the Illumina HiSeq 2500 Platform. *mSystems* **2019**; 4. doi:10.1128/mSystems.00029-19.
 28. Bent SJ, Forney LJ. The tragedy of the uncommon: understanding limitations in the analysis of microbial diversity. *ISME J* **2008**; 2:689–95.
 29. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* **2014**; 15:550.
 30. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A* **2011**; 108(Suppl 1):4680–7.
 31. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. *J Clin Microbiol* **1991**; 29:297–301.
 32. Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. *Nat Protoc* **2008**; 3:163–75.
 33. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. *N Engl J Med* **2005**; 353:1899–911.
 34. Yen S, Shafer MA, Moncada J, Campbell CJ, Flinn SD, Boyer CB. Bacterial vaginosis in sexually experienced and non-sexually experienced young women entering the military. *Obstet Gynecol* **2003**; 102:927–33.
 35. Yoshimura K, Yoshimura M, Kobayashi T, Kubo T, Hachisuga T, Kashimura M. Can bacterial vaginosis help to find sexually transmitted diseases, especially chlamydial cervicitis? *Int J STD AIDS* **2009**; 20:108–11.
 36. Ness RB, Hillier SL, Richter HE, et al. Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. *Obstet Gynecol* **2002**; 100:765.
 37. Tamarelle J, Thiébaud ACM, de Barbeyrac B, Bébéar C, Ravel J, Delarocque-Astagneau E. The vaginal microbiota and its association with human papillomavirus, *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Mycoplasma genitalium* infections: a systematic review and meta-analysis. *Clin Microbiol Infect* **2019**; 25:35–47.
 38. van Houdt R, Ma B, Bruisten SM, Speksnijder AGCL, Ravel J, de Vries HJC. *Lactobacillus iners*-dominated vaginal microbiota is associated with increased susceptibility to *Chlamydia trachomatis* infection in Dutch women: a case-control study. *Sex Transm Infect* **2018**; 94:117–23.
 39. Aghaizu A, Reid F, Kerry S, et al. Frequency and risk factors for incident and redetected *Chlamydia trachomatis* infection in sexually active, young, multi-ethnic women: a community based cohort study. *Sex Transm Infect* **2014**; 90:524–8.
 40. Edwards VL, Smith SB, McComb EJ, et al. The cervicovaginal microbiota-host interaction modulates *Chlamydia trachomatis* infection. *MBio* **2019**; 10. doi:10.1128/mBio.01548-19.
 41. Kong FY, Tabrizi SN, Law M, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. *Clin Infect Dis* **2014**; 59:193–205.
 42. Kashket ER. Bioenergetics of lactic acid bacteria: cytoplasmic pH and osmotolerance. *FEMS Microbiol* **1987**; 46:233–44.
 43. Russell JB, Diez-Gonzalez F. The effects of fermentation acids on bacterial growth. *Adv Microb Physiol* **1998**; 39:205–34.
 44. Alakomi HL, Skyttä E, Saarela M, Mattila-Sandholm T, Latva-Kala K, Helander IM. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. *Appl Environ Microbiol* **2000**; 66:2001–5.
 45. Redondo-Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. *Rev Infect Dis* **1990**; 12:856–72.
 46. Boskey ER, Telsch KM, Whaley KJ, Moench TR, Cone RA. Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification. *Infect Immun* **1999**; 67:5170–5.
 47. Boskey ER, Cone RA, Whaley KJ, Moench TR. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. *Hum Reprod* **2001**; 16:1809–13.
 48. De Backer E, Verhelst R, Verstraelen H, et al. Antibiotic susceptibility of *Atopobium vaginae*. *BMC Infect Dis* **2006**; 6:51.